Aummune’s ASCO 2024 Poster to Showcase AM003 Phase 1 Trial

Aummune, a clinical-stage biopharmaceutical company based in Tel Aviv, Israel, is advancing the development of a pioneering oligonucleotide drug, AM003, for the treatment of solid tumors. The company recently announced that an abstract of their Phase 1 clinical trial for AM003 will be presented at the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO2024) in Chicago, Illinois on June 1, 2024.

AM003 represents a novel and individualized therapeutic approach designed to both induce the death of tumor cells directly and stimulate an anti-tumor immune response. The ongoing Phase 1 trial is an open-label, multicenter, dose-escalation study aimed at assessing the safety and tolerability of AM003 in patients with locally advanced or metastatic solid tumors.

The presentation at ASCO2024 will be given by Dr. Irit Carmi-Levy, General Manager and Chief Scientific Officer of Aummune. She will provide an overview of the progress made in the Phase 1 trial, which has already completed patient enrollment. The preliminary results of this study are anticipated to be available in the third quarter of 2024.

The presentation details are as follows:
- Abstract#: TPS2692
- Title: “Phase 1 study of AM003, a novel individualized immunotherapy, in a basket of advanced solid tumors”
- NCT number: NCT06258330
- Session Title: Poster Session – Developmental Therapeutics—Immunotherapy
- Session Date and Time: June 1, 2024, 9:00am -12:00pm CDT

AM003 is classified as a first-in-class multimodal tumoricidal oligonucleotide. This individualized therapeutic strategy integrates tumor cell eradication with immunotherapy, providing a comprehensive treatment modality. In preclinical trials, AM003 has shown significant potency and selectivity in various human tumor-derived 3D cultures, alongside demonstrating an absence of significant toxicity in non-human primates. Furthermore, it has exhibited both safety and efficacy in murine models of solid tumors.

Aummune is committed to developing innovative therapies for treating solid tumors by combining tumoricidal oligonucleotides with immune-stimulating mechanisms. The company leverages its platform to develop a pipeline of novel oligonucleotide-based therapies, aiming to bring transformative treatments to patients battling advanced cancers.

This critical research and the subsequent presentation underscore Aummune's dedication to pioneering therapeutic options in oncology, particularly for patients with limited treatment alternatives. As the Phase 1 trial progresses, the biopharmaceutical community and patients alike await the forthcoming topline results, which will provide further insights into the potential of AM003 as a groundbreaking treatment for solid tumors.